Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

161
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
161
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

873
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
873
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

107
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
107
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

197
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
197
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

119
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
119
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

73
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
73

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibiotic Consumption and Bloodstream Infections in Patients With Chronic-limb Threatening Ischemia Following Endovascular Therapy in East-west Germany, 2019-2020.

Angiology·2025
Same author

Removing Dust From the German Health Care System by Introducing Health Apps Into Standard Care: Semistructured Interview Study.

JMIR human factors·2023
Same author

Effects of Hospital Digitization on Clinical Outcomes and Patient Satisfaction: Nationwide Multiple Regression Analysis Across German Hospitals.

Journal of medical Internet research·2022
Same author

Healing, surviving, or dying? - projecting the German future disease burden using a Markov illness-death model.

BMC public health·2021
Same author

Economic Value of Data and Analytics for Health Care Providers: Hermeneutic Systematic Literature Review.

Journal of medical Internet research·2020
Same author

Potential Benefits and Risks Resulting From the Introduction of Health Apps and Wearables Into the German Statutory Health Care System: Scoping Review.

JMIR mHealth and uHealth·2020

Related Experiment Video

Updated: Aug 8, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.6K

How to Predict Drug Expenditure: A Markov Model Approach with Risk Classes.

Valeska Hofbauer-Milan1,2, Stefan Fetzer3, Christian Hagist4

  • 1AOK Baden-Württemberg, Stuttgart, Germany. valeska.hofbauer-milan@whu.edu.

Pharmacoeconomics
|February 25, 2023
PubMed
Summary

Future pharmaceutical spending in Germany hinges on high-cost patient trends. Controlling drug prices is crucial for healthcare sustainability, with projections showing potential doubling by 2060.

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Related Experiment Videos

Last Updated: Aug 8, 2025

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.6K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Healthcare Management

Background:

  • Pharmaceutical expenditures have steadily increased, but their drivers and long-term projections remain uncertain.
  • Understanding these drivers is critical for the sustainability of healthcare systems.

Purpose of the Study:

  • To project future pharmaceutical spending in Germany up to 2060.
  • To analyze the influence of various determinants, particularly cost-risk groups, on pharmaceutical expenditure.

Main Methods:

  • Utilized a Markov modeling approach with data from a large statutory sickness fund (approx. 4 million insured).
  • Divided the population into six cost-risk groups, analyzing cost growth rates, survival, and transition probabilities.
  • Computed projections based on scenarios of changing life expectancy and spending trends in different cost-risk groups.

Main Results:

  • Per-capita expenditure may rise over 40% by 2040 if high-cost group spending trends persist.
  • Pharmaceutical expenditures could more than double by 2060, even without increased life expectancy benefits for high-cost groups.
  • Demographic change alone would result in a long-term increase of approximately 15%.

Conclusions:

  • Long-term pharmaceutical spending in Germany is primarily influenced by the future expenditure and life expectancy trends of high-cost patient groups.
  • Strategic pricing of new, expensive pharmaceuticals is essential for maintaining the financial sustainability of the German healthcare system.